When and how to cover for resistant gram-negative bacilli in severe sepsis and septic shock

Current Infectious Disease Reports

Volumn 13, Issue 5, 2011, Pages 416-425

  Hanberger, Håkan ^a   Giske, Christian G ^b   Giamarellou, Helen ^c,d  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d HYGEIA HOSPITAL   (Greece)

Author keywords

lactamase inhibitors Extended spectrum beta lactamase; 16S rRNA methylase; ACHN 490; BAL30072; Carbapenemase; Colistin; Fosfomycin; MDR; Multi drug resistance; Neoglycoside; NXL 104; PDR; Plasmid mediated quinolone resistance; Prevalence of resistance; Resistant Gram Negative Bacilli; Temocillin; Tigecycline; XDR

Indexed keywords

ACHN 490; AMIKACIN; AMINOGLYCOSIDE; AMPICILLIN; ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; AVIBACTAM; BAL 30072; BETA LACTAMASE; CARBAPENEM; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; COLISTIMETHATE; COLISTIN; DORIPENEM; EXTENDED SPECTRUM BETA LACTAMASE; FOSFOMYCIN; IMIPENEM; MEROPENEM; METRONIDAZOLE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SIDEROPHORE MONOBACTAM; SULBACTAM; TEMOCILLIN; TIGECYCLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACINETOBACTER INFECTION; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL IMMUNITY; BACTERIAL MENINGITIS; CLINICAL EFFECTIVENESS; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFICACY; DRUG FATALITY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; GASTROINTESTINAL SYMPTOM; GENETIC RESISTANCE; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE SEPSIS; HAND WASHING; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; KLEBSIELLA PNEUMONIAE INFECTION; LOADING DRUG DOSE; MULTIDRUG RESISTANCE; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; RECOMMENDED DRUG DOSE; SEPSIS; SEPTIC SHOCK; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION;

EID: 80052559061     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-011-0200-1     Document Type: Article

References (83)

1. G Cornaglia H Giamarellou GM Rossolini 2011 Metallo-[beta]-lactamases: a last frontier for [beta]-lactams? Lancet Infect Dis 11 5 381 393 10.1016/s1473-3099(11)70056-1 21530894 10.1016/S1473-3099(11)70056-1 1:CAS:528:DC%2BC3MXlsVGntL4%3D A comprehensive and detailed review in which the problem of the worldwide spread of metallo-β-lactamases is analyzed being a major challenge both for treatment and for infection control policies.
2. PM Hawkey AM Jones 2009 The changing epidemiology of resistance J Antimicrob Chemother 64 Suppl 1 i3 i10 10.1093/jac/dkp256 19675017 10.1093/jac/dkp256 1:CAS:528:DC%2BD1MXhtFagsr3L A review of new mechanism of resistance and trends in global spread of MDR bacteria including ESBLs.
3. L Freire-Moran B Aronsson C Manz, et al. 2011 Critical shortage of new antibiotics in development against multidrug-resistant bacteria-Time to react is now Drug Resist Updat 14 2 118 124 10.1016/j.drup.2011.02.003 21435939 10.1016/j.drup.2011.02.003 This study investigated the status of the antibacterial drug development pipeline of new agents that have entered clinical development.
4. Magiorakos A, Srinivasan A, Carey R, et al. Multidrug resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2011(Accepted Article). doi: 10.1111/j.1469-0691.2011.03570.x.
5. ECDC/EMEA Joint technical report. The bacterial challenge: time to react A call to narrow the gap between multidrug-resistant bacteria in the EU and the development of new antibacterial agents. 2009. http://ecdc.europa.eu/en/ publications/Publications/0909-TER-The-Bacterial-Challenge-Time-to-React.pdf. Accessed June 10 2011. This report describes the gap between the burden of infections due to multidrug-resistant bacteria and the development of new antibiotics.
6. JS Doyle KL Buising KA Thursky, et al. 2011 Epidemiology of infections acquired in intensive care units Semin Respir Crit Care Med 32 2 115 138 10.1055/s-0031-1275525 21506049 10.1055/s-0031-1275525
7. N Goel C Wattal JK Oberoi, et al. 2011 Trend analysis of antimicrobial consumption and development of resistance in non-fermenters in a tertiary care hospital in Delhi, India J Antimicrob Chemother 66 7 1625 1630 10.1093/jac/dkr167 21586594 10.1093/jac/dkr167 1:CAS:528:DC%2BC3MXnsFWksrY%3D
8. Souli M, Galani I, Giamarellou H. Emergence of extensively drug-resistant and pandrug-resistant Gram-negative bacilli in Europe. Euro Surveill. 2008;13(47). A review of mechanism of multidrug resistant of gram-negative bacteria, risk factors for emergence and prevalence in European countries and burden of resistance.
9. KP Abhilash B Veeraraghavan OC Abraham 2010 Epidemiology and outcome of bacteremia caused by extended spectrum beta-lactamase (ESBL)-producing Escherichia coli and Klebsiella spp. in a tertiary care teaching hospital in south India J Assoc Physicians India 58 Suppl 13 17 21563608
10. K Jabeen A Zafar S Irfan, et al. 2010 Increase in isolation of extended spectrum beta lactamase producing multidrug resistant non typhoidal Salmonellae in Pakistan BMC Infect Dis 10 101 10.1186/1471-2334-10-101 20409348 10.1186/1471-2334-10-101
11. M Ofner-Agostini A Simor M Mulvey, et al. 2009 Risk factors for and outcomes associated with clinical isolates of Escherichia coli and Klebsiella species resistant to extended-spectrum cephalosporins among patients admitted to Canadian hospitals Can J Infect Dis Med Microbiol. 20 3 e43 e48 20808455
12. B Uma K Prabhakar S Rajendran Y Lakshmi Sarayu 2010 Prevalence of extended spectrum beta lactamases in Salmonella species isolated from patients with acute gastroenteritis Indian J Gastroenterol 29 5 201 204 10.1007/s12664-010-0044-x 20859716 10.1007/s12664-010-0044-x
13. F Yu Q Chen X Yu, et al. 2011 High prevalence of extended-spectrum beta lactamases among Salmonella enterica Typhimurium isolates from pediatric patients with diarrhea in China PLoS One 6 3 e16801 10.1371/journal.pone.0016801 21390297 10.1371/journal.pone.0016801 1:CAS:528:DC%2BC3MXjtFejtbk%3D The study demonstrates significant multidrug resistance among S.enterica typhimurium within a pediatric population in China, including a higher prevalence of broadspectrum cephalosporin resistance.
14. B Allegranzi S Bagheri Nejad C Combescure, et al. 2011 Burden of endemic health-care-associated infection in developing countries: systematic review and meta-analysis Lancet 377 9761 228 241 10.1016/S0140-6736(10)61458-4 21146207 10.1016/S0140-6736(10)61458-4 A comprehensive review and meta-analysis of burden of health care-associated infection in developing countries.
15. M Johansson DM Phuong SM Walther H Hanberger 2011 Need for improved antimicrobial and infection control stewardship in Vietnamese intensive care units Trop Med Int Health 16 6 737 743 10.1111/j.1365-3156.2011.02753.x 21410602 10.1111/j.1365-3156.2011.02753.x 1:STN:280:DC%2BC3MvpvVGqtg%3D%3D
16. VD Rosenthal 2011 Health-care-associated infections in developing countries Lancet 377 9761 186 188 10.1016/s0140-6736(10)62005-3 21146208 10.1016/S0140-6736(10)62005-3
17. VD Rosenthal DG Maki S Jamulitrat, et al. 2010 International Nosocomial Infection Control Consortium (INICC) report, data summary for 2003-2008, issued June 2009 Am J Infect Control 38 2 95.e2 104.e2 10.1016/j.ajic.2009.12.004 10.1016/j.ajic.2009.12.004 In this recent INICC report on device-associated health-care associated infection rates from 25 developing countries were substantially higher in INICC intensive-care units than CDC/NHSN rates from the USA.
18. VD Rosenthal DG Maki R Salomao, et al. 2006 Device-associated nosocomial infections in 55 intensive care units of 8 developing countries Ann Intern Med 145 8 582 591 17043340 (Pubitemid 46780937)
19. Gagliotti C, Balode A, Baquero F, et al. Escherichia coli and Staphylococcus aureus: bad news and good news from the European Antimicrobial Resistance Surveillance Network (EARS-Net, formerly EARSS), 2002 to 2009. Euro Surveill. 2011;16(11).
20. RA Bonomo 2011 New Delhi metallo-beta-lactamase and multidrug resistance: a global SOS? Clin Infect Dis 52 4 485 487 10.1093/cid/ciq179 21258101 10.1093/cid/ciq179
21. Grundmann H, Livermore DM, Giske CG, et al. Carbapenem-non-susceptible Enterobacteriaceae in Europe: conclusions from a meeting of national experts. Euro Surveill. 2010;15(46). This report provides information on the epidemiologic situation of carbapenem-non-susceptible Enterobacteriaceae in European countries and actions needed to prevent the endemic establishment of carbapenemase-producing Enterobacteriaceae in European hospitals.
22. KK Kumarasamy MA Toleman TR Walsh, et al. 2010 Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study Lancet Infect Dis 10 9 597 602 10.1016/S1473-3099(10)70143-2 20705517 10.1016/S1473-3099(10)70143-2 1:CAS:528:DC%2BC3cXhtVGqsrrP A report of molecular, biological, and epidemiological data on New Delhi metallo-β-lactamase 1 (NDM-1) positive Enterobacteriaceae in India and Pakistan and the importation of the resistance gene into the UK by patients returning from the Indian subcontinent.
23. Nseir S, Blazejewski C, Lubret R, et al. Risk of acquiring multidrug-resistant Gram-negative bacilli from prior room occupants in the intensive care unit. Clin Microbiol Infect. 2010. doi: 10.1111/j.1469-0691.2010. 03420.x.
24. P Gastmeier 2010 Healthcare-associated versus community-acquired infections: a new challenge for science and society Int J Med Microbiol 300 6 342 345 10.1016/j.ijmm.2010.04.007 20452277 10.1016/j.ijmm.2010.04.007
25. K Bush 2010 Alarming [beta]-lactamase-mediated resistance in multidrug-resistant Enterobacteriaceae Curr Opin Microbiol 13 5 558 564 10.1016/j.mib.2010.09.006 20920882 10.1016/j.mib.2010.09.006 1:CAS:528:DC%2BC3cXhtlSnur3K A comprehensive review of b-lactam resistance in Gram-negative pathogens.
26. Jacoby GA. AmpC beta-lactamases. Clin Microbiol Rev. 2009;22(1):161-82, Table of Contents. doi: 10.1128/CMR.00036-08.
27. HS Sader A Hsiung TR Fritsche RN Jones 2007 Comparative activities of cefepime and piperacillin/tazobactam tested against a global collection of Escherichia coli and Klebsiella spp. with an ESBL phenotype Diagn Microbiol Infect Dis 57 3 341 344 10.1016/j.diagmicrobio.2006.08.016 17141461 10.1016/j.diagmicrobio.2006.08.016 1:CAS:528:DC%2BD2sXisVCgtLc%3D (Pubitemid 46330648)
28. K Lee D Yong YS Choi, et al. 2007 Reduced imipenem susceptibility in Klebsiella pneumoniae clinical isolates with plasmid-mediated CMY-2 and DHA-1 beta-lactamases co-mediated by porin loss Int J Antimicrob Agents 29 2 201 206 10.1016/j.ijantimicag.2006.09.006 17204406 10.1016/j.ijantimicag.2006.09.006 1:CAS:528:DC%2BD2sXmtVCgsQ%3D%3D (Pubitemid 46073670)
29. RA Bonomo D Szabo 2006 Mechanisms of multidrug resistance in Acinetobacter species and Pseudomonas aeruginosa Clin Infect Dis 43 Suppl 2 S49 S56 10.1086/504477 16894515 10.1086/504477 1:CAS:528:DC%2BD28XpsFKmtb8%3D This review describes the molecular basis for antibiotic resistance in Acinetobacter species and P. aeruginosa. (Pubitemid 44267140)
30. TR Walsh 2008 Clinically significant carbapenemases: an update Curr Opin Infect Dis 21 4 367 371 10.1097/QCO.0b013e328303670b 18594288 10.1097/QCO.0b013e328303670b
31. MS Ramirez ME Tolmasky 2010 Aminoglycoside modifying enzymes Drug Resist Updat 13 6 151 171 10.1016/j.drup.2010.08.003 20833577 10.1016/j.drup.2010.08. 003 1:CAS:528:DC%2BC3cXhsV2jtL%2FO
32. Y Zhou H Yu Q Guo, et al. 2010 Distribution of 16S rRNA methylases among different species of Gram-negative bacilli with high-level resistance to aminoglycosides Eur J Clin Microbiol Infect Dis 29 11 1349 1353 10.1007/s10096-010-1004-1 20614151 10.1007/s10096-010-1004-1 1:CAS:528:DC%2BC3cXhtlehsbfE
33. LJ Piddock 1999 Mechanisms of fluoroquinolone resistance: an update 1994-1998 Drugs 58 Suppl 2 11 18 10553699 10.2165/00003495-199958002-00003 1:CAS:528:DyaK1MXntFeitbk%3D (Pubitemid 29500079)
34. J Strahilevitz GA Jacoby DC Hooper A Robicsek 2009 Plasmid-mediated quinolone resistance: a multifaceted threat Clin Microbiol Rev 22 4 664 689 10.1128/CMR.00016-09 19822894 10.1128/CMR.00016-09 1:CAS:528:DC%2BD1MXhsVyhsrfI
35. Y Jiang Z Zhou Y Qian, et al. 2008 Plasmid-mediated quinolone resistance determinants qnr and aac(6′)-Ib-cr in extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in China J Antimicrob Chemother 61 5 1003 1006 10.1093/jac/dkn063 18299311 10.1093/jac/dkn063 1:CAS:528:DC%2BD1cXksF2ltrY%3D (Pubitemid 351524439)
36. HW Boucher GH Talbot JS Bradley JE Edwards D Gilbert LB Rice, et al. 2009 Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America Clin Infect Dis 48 1 1 12 10.1086/595011 19035777 10.1086/595011
37. A Kumar D Roberts KE Wood, et al. 2006 Duration of hypotension before initiation of effective antimicrobial therapy is the critical determinant of survival in human septic shock Crit Care Med 34 6 1589 1596 10.1097/01.CCM. 0000217961.75225.E9 16625125 10.1097/01.CCM.0000217961.75225.E9 An extremely important study where it is shown that effective antimicrobial administration within the first hour of documented hypotension is associated with increased survival, whereas there-after each hour of delay over the ensuing 6 hours is associated with decreased survival of 7.6%. (Pubitemid 43810035)
38. H Giamarellou 2010 Multidrug-resistant Gram-negative bacteria: how to treat and for how long Int J Antimicrob Agents 36 Suppl 2 S50 S54 10.1016/j.ijantimicag.2010.11.014 21129924 10.1016/j.ijantimicag.2010.11.014 1:CAS:528:DC%2BC3cXhsFGgsb7P
39. M Souli I Galani A Antoniadou, et al. 2010 An outbreak of infection due to beta-Lactamase Klebsiella pneumoniae Carbapenemase 2-producing K. pneumoniae in a Greek University Hospital: molecular characterization, epidemiology, and outcomes Clin Infect Dis 50 3 364 373 10.1086/649865 20041768 10.1086/649865 1:CAS:528:DC%2BC3cXislSqt74%3D The emergence of KPC-2 positive K. pneumoniae creating the first outbreak in a Greek University Hospital is described in detail where the strain was rapidly disseminated by cross transmission in 38 patients. Most patients received a colistin-containing regimen. Attributable mortality was 22.2% in ICU and 33.3% in non-ICU patients respectively.
40. J Li RL Nation 2006 Old polymyxins are back: is resistance close? Clin Infect Dis 43 5 663 664 10.1086/506571 16886164 10.1086/506571 (Pubitemid 44267132)
41. A Walkty M DeCorby K Nichol, et al. 2009 In vitro activity of colistin (polymyxin E) against 3,480 isolates of gram-negative bacilli obtained from patients in Canadian hospitals in the CANWARD study, 2007-2008 Antimicrob Agents Chemother 53 11 4924 4926 10.1128/AAC.00786-09 19704135 10.1128/AAC.00786-09 1:CAS:528:DC%2BD1MXhtl2itb7L
42. EJ Giamarellos-Bourboulis H Sambatakou I Galani H Giamarellou 2003 In vitro interaction of colistin and rifampin on multidrug-resistant Pseudomonas aeruginosa J Chemother 15 3 235 238 12868548 1:CAS:528:DC%2BD3sXmtFSqur4%3D (Pubitemid 36819310)
43. M Souli PD Rekatsina Z Chryssouli, et al. 2009 Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-beta-lactamase-producing Klebsiella pneumoniae isolates? Antimicrob Agents Chemother 53 5 2133 2135 10.1128/AAC.01271-08 19258266 10.1128/AAC.01271-08 1:CAS:528:DC%2BD1MXlvVGgu7c%3D In 42 K. pneumoniae strains VIM-1 positive, regardless of imipenem MIC, the combination was synergistic (50%) or indifferent (50%) against colistin-susceptible strains, but it was antagonistic (55.6%) against non-colistin-susceptible strains.
44. H Giamarellou G Poulakou 2009 Multidrug-resistant Gram-negative infections: what are the treatment options? Drugs 69 14 1879 1901 10.2165/11315690-000000000-00000 19747006 10.2165/11315690-000000000-00000 1:CAS:528:DC%2BD1MXhtlOrsLbM
45. RY Hachem RF Chemaly CA Ahmar, et al. 2007 Colistin is effective in treatment of infections caused by multidrug-resistant Pseudomonas aeruginosa in cancer patients Antimicrob Agents Chemother 51 6 1905 1911 10.1128/AAC.01015-06 17387153 10.1128/AAC.01015-06 1:CAS:528:DC%2BD2sXmtlKku7g%3D This is the largest retrospective study in the literature in which colistin is shown to be effective in cancer patients, also including cases with neutropenia. (Pubitemid 46903072)
46. H Kallel L Hergafi M Bahloul, et al. 2007 Safety and efficacy of colistin compared with imipenem in the treatment of ventilator-associated pneumonia: a matched case-control study Intensive Care Med 33 7 1162 1167 10.1007/s00134-007-0675-2 17530220 10.1007/s00134-007-0675-2 1:CAS:528:DC%2BD1cXhtV2ltr%2FK In this study, monotherapy with colistin was compared to imipenem monotherapy against XDR and MDR non-formatters strains, indicating, though retrospectively, that colistin monotherapy can be adequate in patients with VAP. (Pubitemid 47036903)
47. FG Rios CM Luna B Maskin, et al. 2007 Ventilator-associated pneumonia due to colistin susceptible-only microorganisms Eur Respir J 30 2 307 313 10.1183/09031936.00156906 17504791 10.1183/09031936.00156906 1:STN:280:DC%2BD2svkslymsw%3D%3D (Pubitemid 47194183)
48. J Garnacho-Montero C Ortiz-Leyba FJ Jimenez-Jimenez, et al. 2003 Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP Clin Infect Dis 36 9 1111 1118 10.1086/374337 12715304 10.1086/374337 1:CAS:528:DC%2BD3sXksFSgtLY%3D (Pubitemid 36549630)
49. M Paul J Bishara A Levcovich, et al. 2010 Effectiveness and safety of colistin: prospective comparative cohort study J Antimicrob Chemother 65 5 1019 1027 10.1093/jac/dkq069 20299494 10.1093/jac/dkq069 1:CAS:528: DC%2BC3cXks1Gms7w%3D
50. R Reina E Estenssoro G Saenz, et al. 2005 Safety and efficacy of colistin in Acinetobacter and Pseudomonas infections: a prospective cohort study Intensive Care Med 31 8 1058 1065 10.1007/s00134-005-2691-4 15983759 10.1007/s00134-005-2691-4 (Pubitemid 41125336)
51. ME Falagas PI Rafailidis E Ioannidou, et al. 2010 Colistin therapy for microbiologically documented multidrug-resistant Gram-negative bacterial infections: a retrospective cohort study of 258 patients Int J Antimicrob Agents 35 2 194 199 10.1016/j.ijantimicag.2009.10.005 20006471 10.1016/j.ijantimicag. 2009.10.005 1:CAS:528:DC%2BD1MXhs1WltbvL A retrospective study in which the authors showed that for strains of P. aeruginosa and A. baumanni, colistin monotherapy is equally as effective as the combination of colistin with meropenem.
52. G Meletis E Tzampaz E Sianou, et al. 2011 Colistin heteroresistance in carbapenemase-producing Klebsiella pneumoniae J Antimicrob Chemother 66 4 946 947 10.1093/jac/dkr007 21393203 10.1093/jac/dkr007 1:CAS:528: DC%2BC3MXjsFKltro%3D
53. W Yau RJ Owen A Poudyal, et al. 2009 Colistin hetero-resistance in multidrug-resistant Acinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance programme J Infect 58 2 138 144 10.1016/j.jinf.2008.11.002 19058855 10.1016/j.jinf.2008.11.002
54. IP Korbila A Michalopoulos PI Rafailidis, et al. 2010 Inhaled colistin as adjunctive therapy to intravenous colistin for the treatment of microbiologically documented ventilator-associated pneumonia: a comparative cohort study Clin Microbiol Infect 16 8 1230 1236 10.1111/j.1469-0691.2009. 03040.x 19732088 10.1111/j.1469-0691.2009.03040.x 1:STN:280: DC%2BC3cjhtVyqtA%3D%3D
55. ME Falagas IA Bliziotis VH Tam 2007 Intraventricular or intrathecal use of polymyxins in patients with Gram-negative meningitis: a systematic review of the available evidence Int J Antimicrob Agents 29 1 9 25 10.1016/j.ijantimicag. 2006.08.024 17126534 10.1016/j.ijantimicag.2006.08.024 1:CAS:528: DC%2BD2sXht1SrsA%3D%3D This review includes the largest number of patients in the literature in which intraventicular or intrathecal colistin was mode of therapy in Gram-negative meningitis. (Pubitemid 44959774)
56. D Plachouras M Karvanen LE Friberg, et al. 2009 Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by gram-negative bacteria Antimicrob Agents Chemother 53 8 3430 3436 10.1128/AAC.01361-08 19433570 10.1128/AAC.01361-08 1:CAS:528: DC%2BD1MXps1ygsrw%3D This study, for the first time in the literature, proves after applying specific methodology, the real serum PKs of intravenous colistin (without measuring colistimethate), showing that colistin displays a prolonged half-life of 14.4h. Based on the low plasma colistin levels after the first dose, the question of the use of a loading dose was raised.
57. C Alberto C Mendes EA Burdmann 2010 Polymyxins-a review focusing on their nephrotoxicity Rev Assoc Med Bras 56 752 758
58. L Fernandez WJ Gooderham M Bains, et al. 2010 Adaptive resistance to the "last hope" antibiotics polymyxin B and colistin in Pseudomonas aeruginosa is mediated by the novel two-component regulatory system ParR-ParS Antimicrob Agents Chemother 54 8 3372 3382 10.1128/AAC.00242-10 20547815 10.1128/AAC.00242-10 1:CAS:528:DC%2BC3cXhtVOmsL7K
59. A Antoniadou F Kontopidou G Poulakou, et al. 2007 Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster J Antimicrob Chemother 59 4 786 790 10.1093/jac/dkl562 17307769 10.1093/jac/dkl562 1:CAS:528:DC%2BD2sXltVKgt7g%3D Selective pressure due to extensive or inadequate colistin use may lead to the emergence of colistin resistance among K. pneumoniae isolates, jeopardizing treatment options in the ICU, potentially increasing morbidity and mortality of critically ill patients and necessiting prudent use of colistin. (Pubitemid 47073420)
60. D Marchaim T Chopra JM Pogue, et al. 2011 Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan Antimicrob Agents Chemother 55 2 593 599 10.1128/AAC.01020-10 21115786 10.1128/AAC.01020-10 1:CAS:528:DC%2BC3MXisVyjsLY%3D
61. H Giamarellou 2007 Colistin: the loss of the last frontier? APUA Newsletter. 25 5
62. DK Matthaiou A Michalopoulos PI Rafailidis, et al. 2008 Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study Crit Care Med 36 3 807 811 10.1097/CCM. 0B013E3181652FAE 18431267 10.1097/CCM.0B013E3181652FAE
63. M Castanheira HS Sader LM Deshpande, et al. 2008 Antimicrobial activities of tigecycline and other broad-spectrum antimicrobials tested against serine carbapenemase- and metallo-beta-lactamase-producing Enterobacteriaceae: report from the SENTRY Antimicrobial Surveillance Program Antimicrob Agents Chemother 52 2 570 573 10.1128/AAC.01114-07 18070960 10.1128/AAC.01114-07 1:CAS:528:DC%2BD1cXhtlSqu7o%3D (Pubitemid 351170830)
64. M Souli FV Kontopidou E Koratzanis, et al. 2006 In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals Antimicrob Agents Chemother 50 9 3166 3169 10.1128/AAC.00322-06 16940120 10.1128/AAC.00322-06 1:CAS:528:DC%2BD28XpsFems7k%3D (Pubitemid 44396429)
65. G Poulakou FV Kontopidou E Paramythiotou, et al. 2009 Tigecycline in the treatment of infections from multi-drug resistant gram-negative pathogens J Infect 58 4 273 284 10.1016/j.jinf.2009.02.009 19344841 10.1016/j.jinf.2009.02. 009
66. Y Cai R Wang B Liang, et al. 2011 Systematic review and meta-analysis of the effectiveness and safety of tigecycline for treatment of infectious disease Antimicrob Agents Chemother 55 3 1162 1172 10.1128/AAC.01402-10 21173186 10.1128/AAC.01402-10 1:CAS:528:DC%2BC3MXktlamtb0%3D
67. EJ Ellis-Grosse T Babinchak N Dartois, et al. 2005 The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam Clin Infect Dis 41 Suppl 5 S341 S353 10.1086/431675 16080072 10.1086/431675 1:CAS:528:DC%2BD2MXhtVWmsrzJ (Pubitemid 41170381)
68. FDA U.S. Food and Drug Administration. FDA Drug Safety Communication: Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. 2010. http://www.fda.gov/Drugs/DrugSafety/ ucm224370.htm. Accessed June 2 2011.
69. AY Peleg BA Potoski R Rea, et al. 2007 Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report J Antimicrob Chemother 59 1 128 131 10.1093/jac/dkl441 17082201 10.1093/jac/dkl441 1:CAS:528:DC%2BD28XhtlChtLzE (Pubitemid 46017915)
70. ME Falagas AC Kastoris AM Kapaskelis DE Karageorgopoulos 2010 Fosfomycin for the treatment of multidrug-resistant, including extended-spectrum [beta]-lactamase producing, Enterobacteriaceae infections: a systematic review Lancet Infect Dis 10 1 43 50 10.1016/s1473-3099(09)70325-1 20129148 10.1016/S1473-3099(09)70325-1 1:CAS:528:DC%2BC3cXntlOhtb0%3D
71. DM Livermore M Warner S Mushtaq, et al. 2011 What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline Int J Antimicrob Agents 37 5 415 419 10.1016/j.ijantimicag.2011.01. 012 21429716 10.1016/j.ijantimicag.2011.01.012 1:CAS:528:DC%2BC3MXksFemsrw%3D
72. ME Falagas S Maraki DE Karageorgopoulos, et al. 2010 Antimicrobial susceptibility of multidrug-resistant (MDR) and extensively drug-resistant (XDR) Enterobacteriaceae isolates to fosfomycin Int J Antimicrob Agents 35 3 240 243 10.1016/j.ijantimicag.2009.10.019 20034765 10.1016/j.ijantimicag.2009.10.019 1:CAS:528:DC%2BC3cXotVehtA%3D%3D
73. A Endimiani G Patel KM Hujer, et al. 2010 In vitro activity of fosfomycin against blaKPC-containing Klebsiella pneumoniae isolates, including those nonsusceptible to tigecycline and/or colistin Antimicrob Agents Chemother 54 1 526 529 10.1128/AAC.01235-09 19901089 10.1128/AAC.01235-09 1:CAS:528: DC%2BC3cXht1Shtro%3D
74. ME Falagas KP Giannopoulou GN Kokolakis PI Rafailidis 2008 Fosfomycin: use beyond urinary tract and gastrointestinal infections Clin Infect Dis 46 7 1069 1077 10.1086/527442 18444827 10.1086/527442 (Pubitemid 351589875)
75. A Michalopoulos S Virtzili P Rafailidis, et al. 2010 Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation Clin Microbiol Infect 16 2 184 186 10.1111/j.1469-0691. 2009.02921.x 19694767 10.1111/j.1469-0691.2009.02921.x 1:CAS:528: DC%2BC3cXitlKqtL0%3D
76. GL Daikos P Petrikkos M Psichogiou, et al. 2009 Prospective observational study of the impact of VIM-1 metallo-beta-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections Antimicrob Agents Chemother 53 5 1868 1873 10.1128/AAC.00782-08 19223638 10.1128/AAC.00782-08 1:CAS:528:DC%2BD1MXlvVGgtLs%3D In 162 consecutive patients with K. pneumoniae bacteraemia the predictive value of an MIC ≤4μg/ml for VIM-1-positive strains indicate a combination of meropenem with another active antibiotic to lower mortality whereas the administration of one active drug was equal to no active drug.
77. JL Crandon CC Bulik DP Nicolau 2009 In vivo efficacy of 1- and 2-gram human simulated prolonged infusions of doripenem against Pseudomonas aeruginosa Antimicrob Agents Chemother 53 10 4352 4356 10.1128/AAC.00282-09 19770286 1:CAS:528:DC%2BD1MXht1KkurvO Advantageous PD target attainment of 1 and 2g doses of doripenem given as a 4h infusion in mice and humans even for P. aeruginosa strains with MIC 8-16μg/ml were observed.
78. JM Adams-Haduch BA Potoski HE Sidjabat, et al. 2009 Activity of temocillin against KPC-producing Klebsiella pneumoniae and Escherichia coli Antimicrob Agents Chemother 53 6 2700 2701 10.1128/AAC.00290-09 19332667 10.1128/AAC.00290-09 1:CAS:528:DC%2BD1MXntFGktrw%3D
79. AS Levin CE Levy AE Manrique, et al. 2003 Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam Int J Antimicrob Agents 21 1 58 62 12507838 10.1016/S0924-8579(02)00276-5 1:CAS:528:DC%2BD38XpvVWrurs%3D (Pubitemid 36043975)
80. A Endimiani KM Hujer AM Hujer, et al. 2009 ACHN-490, a neoglycoside with potent in vitro activity against multidrug-resistant Klebsiella pneumoniae isolates Antimicrob Agents Chemother 53 10 4504 4507 10.1128/AAC.00556-09 19770287 1:CAS:528:DC%2BD1MXht1KkurnI
81. M Bassetti F Ginocchio DR Giacobbe M Mikulska 2011 Development of antibiotics for Gram-negatives: where now? Clin Investig. 1 211 227 10.4155/cli.10.31 10.4155/cli.10.31 1:CAS:528:DC%2BC3MXjvVKgtrk%3D
82. Y Carmeli M Akova G Cornaglia, et al. 2010 Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control Clin Microbiol Infect 16 2 102 111 10.1111/j.1469-0691.2009.03115.x 20085604 10.1111/j.1469-0691.2009.03115.x 1:CAS:528:DC%2BC3cXitlKqt70%3D
83. AL Pakyz M Oinonen RE Polk 2009 Relationship of carbapenem restriction in 22 university teaching hospitals to carbapenem use and carbapenem-resistant Pseudomonas aeruginosa Antimicrob Agents Chemother 53 5 1983 1986 10.1128/AAC.01535-08 19273670 10.1128/AAC.01535-08 1:CAS:528: DC%2BD1MXlvVGgur4%3D